Proteasome inhibition as a novel therapeutic target in human cancer.

By S. Rajkumar, P. Richardson, T. Hideshima, K. Anderson. Journal of Clinical Oncology, 2005

597 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. (2007, background): “, 2003), which have been postulated to act principally by inhibiting NF-kB (Rajkumar et al., 2005).”
Targeting Apoptosis Pathways in Cancer Therapy (2005, background): “They have also been shown to inhibit angiogenesis and metastasis in vivo.(29,95) The effects of these agents may be selective to cancer cells because they induce apoptosis in proliferating or transformed cells.”
The Concept of Synthetic Lethality in the Context of Anticancer Therapy (2005, background): “The proteasomal inhibitor bortezomib is well tolerated in humans and was recently approved for the treatment of multiple myelom”
HSP90 and the chaperoning of cancer (2005, background): “Similar concerns were raised during the development of proteasome inhibitors that, nevertheless, have demonstrated useful anticancer activity, especially against multiple myelom”